FDU-PB-22 (naphthalen-1-yl 1-[(4-fluorophenyl)methyl]-1H-indole-3-carboxylate) is a synthetic cannabinoid. It is considered to be a constituent of illicit smoking mixtures "spice".

SDB-005 is a synthetic cannabinoid. It is considered to be a constituent of illicit smoking mixtures "spice".

5F-SDB-006 is a synthetic cannabinoid. It is considered to be a constituent of illicit smoking mixtures "spice".

BAY-59-3074 is a novel, selective cannabinoid CB(1)/CB(2) receptor ligand (K(i) = 55.4, 48.3, and 45.5 nM at rat and human cannabinoid CB(1) and human CB(2) receptors, respectively), with partial agonist properties at these receptors in guanosine 5-[gamma(35)S]-thiophosphate triethyl-ammonium salt ([(35)S]GTPgammaS) binding assays. It displays anti-hyperalgesic and antiallodynic properties in rat models of chronic neuropathic and inflammatory pain. BAY-59-3074 may offer a valuable therapeutic approach to treat diverse chronic pain conditions.

L-768242 (GW-405,833) is a potent and selective partial agonist for the cannabinoid CB2 receptor with marked anti-inflammatory and anti-hyperalgesic activity in high doses. L-768242 suppresses pathological pain in preclinical models without unwanted central side effects of CB1 agonists. L-768242 dose-dependently reversed established mechanical allodynia in models of neuropathic (i.e. partial sciatic nerve ligation (PSNL) model) and inflammatory (i.e. complete Freund's adjuvant (CFA) model) pain. Despite substantial penetration to the CNS L-768242 did not produce cannabimimetic deficits below doses of 100 mg/kg i.p. Anti-allodynic efficacy of L-768242 was opioid-independent as systemic administration of naltrexone did not block the anti-hyperalgesic or antinociceptive effects of L-768242. In in vitro studies, L-768242 was reported to behave as a partial agonist at human CB2 receptors and, alternately, a potent inverse agonist at both human and rat CB2 receptors and a weak agonist at rat CB1 receptors. L-768242 was suggested to act as a non-competitive CB1 antagonist as L-768242 non-competitively antagonized CP55,940-induced adenylyl cyclase activity, ERK1/2 phosphorylation, PIP2 signaling and CB1 internalization in vitro in HEK cells transfected with CB1 and showed a complex, time-dependent effect on arrestin recruitment in CHO cells. Anti-allodynic efficacy of L-768242 is CB1-dependent but does not seem to involve engagement of the CB1 receptor’s orthosteric site.

SDB-006 is a cannabimimetic indole that binds the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with EC50 values of 19 and 134 nM, respectively. SDB-006 was discovered during research of the related compound JWH-018 adamantyl carboxamide, which has been sold illicitly in herbal blends.

PSNCBAM-1 is a novel negative allosteric modulator of the cannabinoid CB1 receptor. This molecule is shown to produce acute hypophagia and weight loss in male SD rats, and therefore may represent an alternative approach to the current strategies for the treatment of obesity. PSNCBAM-1 allosteric antagonism may provide viable therapeutic alternatives to orthosteric CB1 antagonists/inverse agonists in the treatment of CNS disease. No adverse or toxic effects were seen after long-term PSNCBAM-1 administration in vivo.

NIDA-41020 is a functional CB1 cannabinoid receptor antagonist.